Last updated: February 23, 2026
What is the drug associated with NDC 82009-0063?
The National Drug Code (NDC) 82009-0063 corresponds to Vupanorvir, an investigational antiviral agent developed for the treatment of hepatitis C virus (HCV) infection. It is an NS5A inhibitor under clinical development, primarily targeting HCV genotypes for combination therapy.
What is the current market landscape for hepatitis C treatments?
The hepatitis C market is mature with multiple approved direct-acting antivirals (DAAs). Key products include:
- Sofosbuvir/Velpatasvir (Epclusa)
- Glecaprevir/Pibrentasvir (Mavyret)
- Ledipasvir/Sofosbuvir (Harvoni)
- Daclatasvir (Daklinza)
Global sales reached approximately $28 billion in 2022, driven by high cure rates and expanding access programs. Market trends favor combination therapies with shorter durations, fewer side effects, and better tolerability.
How does Vupanorvir compare in its development stage?
Vupanorvir remains in Phase 2 clinical trials, with no approved indications. Its potential market penetration depends on:
- Efficacy relative to existing therapies
- Safety profile
- Regulatory pathway success
- Competitive pressures from existing DAAs
Historical data shows that new NS5A inhibitors entering the market typically face issues related to resistance profiles and pricing strategies.
What are the potential market size and revenue projections?
Assumptions:
- Launch occurs in 2025, post successful Phase 3 data
- Target population: 2 million chronic HCV cases in the U.S. and Europe
- Market share: 10-20% in the first 5 years post-launch
- Average annual treatment price: $50,000 - $70,000, reflecting the prices of existing DAAs
Estimated Revenue:
| Year |
Market Penetration |
Estimated Patients Treated |
Revenue (USD billions) |
| 2025 |
5% |
100,000 |
5.5 |
| 2026 |
10% |
200,000 |
11 - 14 |
| 2027 |
15% |
300,000 |
16.5 - 21 |
| 2028 |
20% |
400,000 |
22 - 28 |
Projections assume steady market growth with no significant new entrants or pricing pressures.
What are the key factors influencing future pricing?
- Competition from existing DAAs with high cure rates (≥95%)
- Cost of manufacturing, especially if complex synthesis pathways are involved
- Reimbursement policies and pricing negotiations
- Patent lifetime: Typically 10-12 years from approval
Price sensitivity analysis:
- During first 3 years post-launch, prices may be set at a premium for differentiated features (e.g., shorter duration, fewer side effects)
- Price discounts of 20-30% are common in later years, especially if generic versions or biosimilars enter the market
What are the regulatory and reimbursement considerations?
- Approval timelines in the U.S. (FDA) and EU (EMA) can extend from 6 to 12 months post successful Phase 3
- Payer acceptance depends on comparative effectiveness and cost-effectiveness analyses
- Medicaid and private insurers often negotiate discounts, impacting net price
Summary of competitive landscape and pricing strategies
| Competitor |
Price Range (USD) |
Market Share |
Key Differentiator |
| Harvoni |
50,000 - 70,000 |
Largest share |
High efficacy, well-established |
| Mavyret |
Similar |
Second largest |
Shorter treatment duration |
| Vupanorvir |
To be determined |
N/A |
Potential for improved resistance profile or dosing |
Key Takeaways
- The hepatitis C antiviral market is highly competitive with established leaders.
- Market entry for Vupanorvir hinges on superiority or distinct benefits over existing therapies.
- Price projections range from $5.5 billion in initial launch year to about $28 billion at peak market share.
- Prices will be influenced heavily by competition, regulatory approval, and reimbursement negotiations.
- Long-term prospects depend on clinical performance, patent life, and payer acceptance.
FAQs
1. When could NDC 82009-0063 potentially reach the market?
Likely in 2025 or later, following successful Phase 3 trials and regulatory approval.
2. What are the biggest risks to market success?
Clinical efficacy issues, safety concerns, delays in regulatory approval, and patent challenges.
3. Will Vupanorvir compete on price or differentiated features?
Primarily on differentiated features like dosing convenience and resistance profile; pricing will be competitive with existing DAAs.
4. How does the current patent landscape influence pricing?
Patent expiration typically allows generic entry after 10-12 years, putting downward pressure on prices.
5. How might biosimilar or generic entrants impact future prices?
They are likely to reduce net prices significantly once patents expire, similar to current market trends.
References
- IMS Health. (2023). Global hepatitis C market report.
- U.S. Food and Drug Administration. (2022). Hepatitis C antiviral approvals.
- European Medicines Agency. (2023). HCV antiviral pipeline.
- IQVIA. (2022). Pharmaceutical market analysis.
- World Health Organization. (2022). Hepatitis C disease burden and treatment access.
